Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11213364 | 0.73 | LTA4H (0.45) | LTA4HTSHRCA4 | |
| SCHEMBL28017927 | 0.72 | LTA4H (0.50) | LTA4HTSHRCA4 | |
| SCHEMBL13289 | 0.72 | LTA4H (0.50) | LTA4HTSHRCA4 | |
| SCHEMBL9841149 | 0.72 | LTA4H (0.39) | LTA4HTSHRCA4 | |
| SCHEMBL17733779 | 0.71 | LTA4H (0.35) | LTA4HTSHRCA4 | |
| SCHEMBL2251099 | 0.71 | LTA4H (0.35) | LTA4HTSHRCA4 | |
| SCHEMBL11681119 | 0.70 | LTA4H (0.47) | LTA4HTSHRCA4 | |
| SCHEMBL8113527 | 0.70 | LTA4H (0.47) | LTA4HTSHRCA4 | |
| SCHEMBL11871889 | 0.70 | LTA4H (0.47) | LTA4HTSHRCA4 | |
| Iodide SCHEMBL5553135 | 0.70 | LTA4H (0.47) | LTA4HTSHRCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143293-B2 | disease caused by c-Abl kinase, c-Kit kinase, oncogenic forms, aberrant fusion proteins and polymorphs; 1-(3-t-butylisoxazol-5-yl)-3-(2-fluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)urea | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-7863294-B2 | Heterocycle derivatives as histone deacetylase (HDAC) inhibitors | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-01-04 | — | — | US | disclosed |
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-02-19 | — | — | US | disclosed |
| EP-1993536-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20080269267-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269254-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080261961-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-23 | — | — | US | disclosed |
| US-20070249599-A1 | Novel Chemical Compounds | DUFFY KEVIN J | 2007-10-25 | — | — | US | disclosed |
| WO-2007103755-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| EP-1718642-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082901-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249599-A1 | Novel Chemical Compounds | HIPK3, HIPK1, HIPK4 | LTA4H 3276/4885TSHR 4520/4885CA4 4702/4885 |
| US-20080269254-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, BRAF, RET | LTA4H 2668/4885TSHR 676/4885CA4 1804/4885 |
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | PIK3CA, BTK, PI4KA | LTA4H 1359/4885TSHR 1457/4885CA4 3279/4885 |
| US-20080269267-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | BRAF, RET, KIT | LTA4H 2613/4885TSHR 584/4885CA4 1380/4885 |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, PRKACA, BRAF | LTA4H 1992/4885TSHR 752/4885CA4 1739/4885 |
| US-20080261961-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, BRAF, RET | LTA4H 2668/4885TSHR 676/4885CA4 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.